- Home
- PAXS vs CDNA Comparison
PAXS vs CDNA Comparison
Compare PAXS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- CDNA
- Stock Information
- Founded
- PAXS 2021
- CDNA 1998
- Country
- PAXS United States
- CDNA United States
- Employees
- PAXS N/A
- CDNA N/A
- Industry
- PAXS Investment Managers
- CDNA Medical Specialities
- Sector
- PAXS Finance
- CDNA Health Care
- Exchange
- PAXS Nasdaq
- CDNA Nasdaq
- Market Cap
- PAXS 723.1M
- CDNA 712.2M
- IPO Year
- PAXS N/A
- CDNA 2014
- Fundamental
- Price
- PAXS $16.26
- CDNA $13.53
- Analyst Decision
- PAXS
- CDNA Buy
- Analyst Count
- PAXS 0
- CDNA 8
- Target Price
- PAXS N/A
- CDNA $26.86
- AVG Volume (30 Days)
- PAXS 195.0K
- CDNA 1.5M
- Earning Date
- PAXS 01-01-0001
- CDNA 11-03-2025
- Dividend Yield
- PAXS 11.72%
- CDNA N/A
- EPS Growth
- PAXS N/A
- CDNA N/A
- EPS
- PAXS N/A
- CDNA 1.00
- Revenue
- PAXS N/A
- CDNA $340,826,000.00
- Revenue This Year
- PAXS N/A
- CDNA $13.02
- Revenue Next Year
- PAXS N/A
- CDNA $12.85
- P/E Ratio
- PAXS N/A
- CDNA $13.56
- Revenue Growth
- PAXS N/A
- CDNA 14.72
- 52 Week Low
- PAXS $12.57
- CDNA $10.96
- 52 Week High
- PAXS $15.93
- CDNA $32.97
- Technical
- Relative Strength Index (RSI)
- PAXS 70.54
- CDNA 52.36
- Support Level
- PAXS $15.46
- CDNA $13.12
- Resistance Level
- PAXS $16.46
- CDNA $13.80
- Average True Range (ATR)
- PAXS 0.10
- CDNA 0.67
- MACD
- PAXS 0.02
- CDNA 0.16
- Stochastic Oscillator
- PAXS 72.16
- CDNA 63.39
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.